Mémoire de l'IPIC sur le Règlement de 2017 modifiant le Règlement sur les médicaments brevetés (avis de conformité)

Position de l'IPIC

Given the consultation that has already occurred with both innovator and generic companies, as well as members of the bar and bench, prior to the release of these Proposed Regulations, we will not be engaging with the substantive legislative choices that have been made. Further, while members of the profession certainly have comments and concerns about these substantive choices, it is difficult for IPIC to be the channel for those concerns given that its members represent both innovator and generic companies, who often have different views.

However, we believe there is one point worth reiterating which is that the Federal government must ensure that the Court has sufficient resources to manage the additional complexity of NOC actions.